Revenue from operations during the quarter under review stood at Rs 5,139.6 crore as against Rs 3,964.4 crore in the year-ago period, up 29.6 per cent
The company has received approval from the US Food and Drug Administration (USFDA) to market Gabapentin tablets which are indicated for the management of postherpetic neuralgia (PHN)
The final approval granted by the US Food and Drug Administration (USFDA) to the company's US arm Zydus Pharmaceuticals Inc is for the tablets of strengths 25 mg and 50 mg, it said in a regulatory filing
As per the USFDA, it may designate a drug as a CGT after determining that there is inadequate generic competition for that drug
The company has also received final approval from the US Food and Drug Administration (USFDA) to market Pregabalin capsules in multiple strengths, the Ahmedabad-based drug maker said in a statement.
The company has received approval from the US Food and Drug Administration to market the drug in the strengths of 20mg and 40mg, the company said in a statement.
The approval by the US Food and Drug Administration (USFDA) is for Acetazolamide tablets of strengths 125 mg and 250 mg, Zydus Lifesciences said in a regulatory filing
